Fig. 2: LIPTER deficiency disrupts LD balance of hiPSC-CMs.
From: Lipid droplet-associated lncRNA LIPTER preserves cardiac lipid metabolism
a, Heat map showing top changed metabolites in LIPTERKO versus WT hiPSC-CMs at day 40 of differentiation. b, Oil Red O lipid staining and cTnT immunostaining (first two columns); Nile Red and cTnT co-staining (third column); LIPTER RNA FISH and Lipid Deep Red co-staining (fourth column) in WT, LIPTERKO and LIPTERKO/OE hiPSC-CMs. c, Quantification of the ratios of Oil Red O+ areas to cTnT+ CM areas (n = 4 independent experiments). d, Schematic of lipid uptake and LD mobilization analysis in palmitic acid (palmitate)-treated WT and LIPTERKO hiPSC-CMs. e, Uptake of Rhodamine B-palmitic acid by whole hiPSC-CMs (n = 3 independent experiments). f,g, Representative fluorescence images of LD accumulation/distribution in WT and LIPTERKO hiPSC-CMs treated with 200 μM palmitate for 6 h (f), followed by palmitate depletion for an additional 12 h (g). h, Quantification of relative LD densities in whole CMs, and in 1/2 cytosolic and 1/2 nucleus surrounding areas in CMs (n = 4 independent experiments). i, Measurement of Rhodamine B fluorescence levels in mitochondria isolated from hiPSC-CMs post treatment with Rhodamine B-palmitic acid for 2 h (n = 4 independent experiments). In c, e, h and i, bars are presented as mean ± s.e.m. Unpaired two-tailed t-test is used for comparison. Source numerical data are available in source data.
